martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

VistaShares Marks the One-Year Anniversary of its Artificial Intelligence Supercycle ETF (AIS)

View original at globenewswire.com
VistaShares Marks the One-Year Anniversary of its Artificial Intelligence Supercycle ETF (AIS) BOSTON, Dec…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Without lesser known companies around the world that might not be on investor radars, the AI revolution cannot proceed

    80% confidence
  • AIS was built to give people exposure to the full AI supply chain and the real engines of this Supercycle

    80% confidence
  • A year later, the fund has emerged as the top-performing fund in the AI Infrastructure sector

    80% confidence
  • From day one, we knew thematic investing needed a reset. Investors should be able to invest in a major technology shift without guessing which single company will win

    80% confidence
  • The approach behind both funds is clearly resonating with investors and advisors who understand the role that AI and electrification investments can play in a portfolio but who also understand the importance of having diversified exposure outside of the category's boldfaced names

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com